BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Healthtrust
Baxter
Mallinckrodt
Accenture
Covington
Chubb
Cantor Fitzgerald
Farmers Insurance
Medtronic

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,479

« Back to Dashboard

Which drugs does patent 8,338,479 protect, and when does it expire?

Patent 8,338,479 protects LUMIGAN and is included in one NDA.

This patent has thirty-two patent family members in twenty-one countries.
Summary for Patent: 8,338,479
Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/351,383
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,338,479

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,338,479

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,524,777 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
9,241,918 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
7,851,504 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,933,120 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,278,353 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,586,630 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,309,605 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,299,118 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
9,155,716 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
8,772,338 Enhanced bimatoprost ophthalmic solution ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,338,479

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055050 ➤ Subscribe
Austria 431152 ➤ Subscribe
Australia 2006227757 ➤ Subscribe
Brazil PI0607447 ➤ Subscribe
Canada 2585691 ➤ Subscribe
China 101137383 ➤ Subscribe
China 102240292 ➤ Subscribe
Germany 602006006762 ➤ Subscribe
Denmark 1753434 ➤ Subscribe
European Patent Office 1753434 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Cipla
Federal Trade Commission
Fish and Richardson
Julphar
Moodys
Argus Health
Harvard Business School
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot